Alimera Sciences (NASDAQ:ALIM) posted its earnings results on Monday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.03), Fidelity Earnings reports. The business had revenue of $10.86 million during the quarter, compared to the consensus estimate of $12.97 million.

Shares of NASDAQ:ALIM traded down $0.24 on Tuesday, hitting $0.65. The company had a trading volume of 12,636 shares, compared to its average volume of 76,945. Alimera Sciences has a 52-week low of $0.72 and a 52-week high of $1.21. The business has a 50 day moving average of $0.90.

Several research firms have weighed in on ALIM. Zacks Investment Research lowered EXACT Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. HC Wainwright reissued a “buy” rating on shares of Interpace Diagnostics Group in a report on Friday, June 21st. Finally, Craig Hallum reissued a “hold” rating and issued a $153.00 target price (up previously from $128.00) on shares of Cavco Industries in a report on Tuesday, May 28th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $2.50.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Further Reading: Buy-Side Analysts

Earnings History for Alimera Sciences (NASDAQ:ALIM)

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.